What does CellCentric do?
CellCentric is a clinical-stage biotechnology company focused on developing new cancer therapies. Its flagship treatment, Inobrodib, is an oral small molecule drug designed to target p300/CBP, thereby lowering the expression of key cancer drivers such as MYC and IRF4.
How much did they raise?
The company raised $120M in Series C funding, led by RA Capital Management with new participation from Forbion, and further supported by Avego Bioscience Capital and BrightEdge.
What are their plans for the money?
With the new funds, CellCentric plans to advance the clinical development and potential commercialization of Inobrodib, aiming to offer a safer, home-based treatment option for cancer patients, especially those suffering from multiple myeloma.
What have they achieved so far?
CellCentric has already shown promising progress with Inobrodib, evidenced by its good safety profile in early clinical trials, positioning it as a viable alternative for patients unable to access or tolerate existing treatments.
